Sarcoma  >>  Jemperli (dostarlimab-gxly) 
Welcome,         Profile    Billing    Logout  

9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jemperli (dostarlimab-gxly) / GSK
2019-002662-12: A multicentric randomized phase II/III evaluating TSR-042 (anti-PD-1 mAb) in combination with Niraparib (parpi) versus Niraparib alone compared to chemotherapy in the treatment of metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy Etude de phase II/III, randomisée, multicentrique évaluant le TSR-042 (anti-PD-1 mAb) associé au Niraparib versus le Niraparib seul comparé à la chimiothérapie chez des patientes atteintes d’un carcinosarcome métastasique ou en récidive de l’ovaire ou de l’endomètre après une chimiothérapie de première intention

Not yet recruiting
2/3
196
Europe
NIRAPARIB, DOSTARLIMAB, TSR-042, Capsule, Powder for solution for infusion, Concentrate for solution for infusion, Solution for infusion, Solution for solution for infusion, NIRAPARIB, GEMCITABINE, PACLITAXEL, DOXORUBICINE LIPOSOMALE PEGYLEE, TOPOTECAN, DOXORUBICINE IV
ARCAGY-GINECO, TESARO
metastatic or recurrent endometrial or ovarian carcinosarcoma, metastatic or recurrent endometrial or ovarian carcinosarcoma, Diseases [C] - Cancer [C04]
 
 
ROCSAN, NCT03651206: Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib

Hourglass Jan 2019 - Jan 2019 : Initiation of P2/3 ROCSAN trial for recurrent ovarian carcinosarcoma
Active, not recruiting
2/3
196
Europe
Niraparib, Niraparib + TSR-042 (Dostarlimab), Chemotherapy Drugs
ARCAGY/ GINECO GROUP, Tesaro, Inc.
Ovarian Carcinosarcoma, Endometrial Carcinosarcoma
12/24
06/25
2016-004368-21: Phase II study on clear cells sarcoma Studio sul sarcoma a cellule chiare in fase avanzata

Not yet recruiting
2
21
Europe
Dostarlimab, [TSR-042], Solution for infusion
ITALIAN SARCOMA GROUP, GSK-TESARP
Advanced clear cells sarcoma Sarcoma a cellule chiare in fase avanzata, Advanced clear cells sarcoma Sarcoma a cellule chiare in fase avanzata, Diseases [C] - Cancer [C04]
 
 
ACCeSs, NCT04274023: Study on TSR-042 in Advanced Clear Cell Sarcoma

Terminated
2
3
Europe
TSR-042
Italian Sarcoma Group, GlaxoSmithKline
Sarcoma, Clear Cell
01/24
01/24
Pan-MSI-ACSE, NCT06333314: Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

Not yet recruiting
2
120
Europe
Dostarlimab, Chemotherapy
UNICANCER, National Cancer Institute, France, GlaxoSmithKline
Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma, Small Bowel Adenocarcinoma, Duodenum Adenocarcinoma, Gastric Adenocarcinoma
10/28
09/30
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
NCT05559879: Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

Recruiting
1/2
37
US
Cabo + Dostarlimab
University of Alabama at Birmingham
Gynecologic Cancer, Carcinoma, Uterine Cancer, Endometrial Cancer
12/24
12/25
STARKAP, NCT05646082: Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi Sarcoma

Recruiting
1
20
Europe
Dostarlimab in Combination Antiretroviral Therapy
Imperial College London
Refractory HIV Associated Kaposi Sarcoma
05/24
09/25
SCOOP, NCT04544995 / 2020-002359-39: Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Pediatric Participants With Solid Tumors

Suspended
1
116
Europe, RoW
Niraparib, Dostarlimab
GlaxoSmithKline
Neoplasms
09/28
04/29

Download Options